Every Form 4 that Pacira BioSciences, Inc. (PCRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCRX filings page.
Pacira BioSciences, Inc. (PCRX) reported that its Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share in an open-market transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2025. Following this sale, Slonin directly holds 216,383.646 shares of Pacira common stock, which include 511.471 shares acquired through the company’s employee stock purchase plan in June 2026.
Pacira BioSciences director Samit Hirawat received new equity awards. He was granted 6,405 restricted stock units of common stock, which will vest on June 10, 2027 if he remains in continuous service with the company through that date.
He was also granted stock options covering 10,891 shares of common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, and expire on June 10, 2036. Following these awards, he holds 6,405 common shares and options on 10,891 shares directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
Pacira BioSciences director Christopher Christie received new equity compensation awards. He was granted 6,405 restricted stock units that vest on June 10, 2027, as long as he remains in continuous service with the company through that date. Each unit represents one share of common stock. He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share, which vests and becomes exercisable on June 10, 2027 and expires on June 10, 2036. Following these awards, Christie directly holds 23,059 shares of Pacira common stock. These are compensation-related grants, not open-market purchases or sales.
Pacira BioSciences director Thomas G. Wiggans received a stock option grant for 32,675 shares of common stock. The option has an exercise price of $23.42 per share and expires on June 10, 2036. One-third of the option vests on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments over the following two years, as long as he remains in continuous service. After this grant, he holds options for 32,675 shares.
Pacira BioSciences director Alethia Young reported receiving equity compensation. On June 10, 2026, she was granted 6,405 restricted stock units, each representing one future share of common stock, and 10,891 stock options with an exercise price of $23.42 per share.
Both the restricted stock units and options vest on June 10, 2027, provided she remains in continuous service with Pacira through that date. Following the grant, she directly holds 17,798 shares of common stock, plus the newly granted options for 10,891 additional shares.
Pacira BioSciences director Michael J. Yang received new equity awards as part of his compensation. On June 10, 2026, he was granted 6,405 restricted stock units that will vest on June 10, 2027, if he remains in continuous service. Each unit converts into one share of common stock at vesting.
He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share. This option becomes exercisable on June 10, 2027, subject to the same service requirement, and expires on June 10, 2036. Following these awards, he directly holds 19,798 shares of common stock.
Pacira BioSciences director Marcelo Bigal received new equity awards as part of compensation. He was granted 6,405 restricted stock units, each representing one share of common stock, which vest on June 10, 2027 if he remains in continuous service with the company.
He also received a stock option covering 10,891 shares of common stock at an exercise price of $23.42 per share. This option vests on June 10, 2027 under the same service condition and expires on June 10, 2036. Following the grant, his direct holdings of common stock total 17,798 shares.
Pacira BioSciences director Mark Froimson received equity compensation consisting of restricted stock units and stock options. He was granted 6,405 restricted stock units, each representing the right to receive one share of Pacira common stock. These units vest on June 10, 2027, if he remains in continuous service through that date, and will then convert into common shares.
He was also granted 10,891 stock options to buy Pacira common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, subject to the same continuous service condition, and expire on June 10, 2036. Following the grant, Froimson directly holds 26,541 shares of Pacira common stock.
Pacira BioSciences director Laura Brege reported equity awards consisting of restricted stock units and stock options. She received 6,405 shares of common stock as a grant, bringing her directly held common shares to 30,120. She was also granted options for 10,891 shares at an exercise price of $23.42 per share.
The 6,405 restricted stock units vest on June 10, 2027, if she remains in continuous service with Pacira through that date. The stock options also vest on June 10, 2027 under the same service condition and will expire on June 10, 2036 if not exercised.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported a routine tax-related share disposition. On a restricted stock unit vesting, 3,187 shares of common stock were withheld by the company to cover tax obligations at $22.32 per share. After this withholding, Riker directly holds 68,399.242 shares of Pacira common stock, indicating the transaction was a standard compensation-related event rather than an open-market sale.
Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a routine tax-related share disposition. On the reported date, 4,728 shares of common stock were withheld by the company to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin directly holds 218,912.175 shares of Pacira BioSciences common stock. This event reflects tax withholding rather than an open-market sale or purchase.
Pacira BioSciences Chief Administrative Officer Kristen Williams sold 10,259 shares of common stock in an open-market trade at $22.27 per share on June 4, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
One day earlier, on June 3, 2026, 8,528 shares were withheld at $22.32 per share to cover tax obligations upon vesting of a restricted stock unit award, which is a non-market, compensation-related event. After these transactions, Williams directly holds 167,062 Pacira shares.
Pacira BioSciences Chief Financial Officer Shawn Cross reported option-related transactions in company common stock. On April 23, 2026, he exercised stock options to acquire 12,941 shares at $16.45 per share and sold 12,941 shares in open-market trades at a weighted average price of $25.16, within a range of $25.00 to $25.41. The filing shows these moves were made under a pre-established Rule 10b5-1 trading plan. After the transactions, he directly owned 105,341 shares of Pacira common stock.
Pacira BioSciences Chief Financial Officer Shawn Cross exercised stock options and sold shares in a pre-planned set of trades. Over April 20–22, he exercised options for 12,059 shares of common stock at an exercise price of $16.45 per share and sold the same number of shares in open-market transactions at weighted average prices around $25.01–$25.14 per share.
After these transactions, he directly holds 105,341 shares of Pacira common stock. The filing states that the option exercises and sales were carried out under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic.
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.
The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.
Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.
Pacira BioSciences, Inc. director Mark Froimson reported an open-market sale of 500 shares of common stock at $21.81 per share. After this transaction, he directly holds 20,136 shares. This filing reflects a relatively small sale compared with his remaining reported ownership.
Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of $0 per share as an acquisition, increasing his directly held common stock to 105,341 shares.
The restricted stock units vest in four equal annual installments beginning on February 15, 2027, if Cross remains in continuous service with Pacira on each vesting date. Each unit represents the right to receive one share of Pacira common stock upon vesting.
Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to Chief Commercial Officer Brendan Teehan. On February 11, 2026, he acquired 51,714 shares of common stock at a price of $0 under a grant classified as an award or other acquisition.
The award represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. After this grant, Teehan directly beneficially owns 100,934.268 shares of Pacira common stock.
RIKER LAUREN reported acquisition or exercise transactions in a Form 4 filing for PCRX. The filing lists transactions totaling 19,273 shares. Following the reported transactions, holdings were 71,586 shares.
SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
Pacira BioSciences, Inc. reported that Chief Medical Officer Jonathan Slonin received an equity award of 54,546 shares of common stock on February 11, 2026. The award was granted at a price of $0 per share and is structured as restricted stock units.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as Slonin remains in continuous service with the company on each vesting date. After this grant, he beneficially owns 226,901.175 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to its Chief Executive Officer and director, Frank D. Lee. On February 11, 2026, he acquired 261,818 shares of common stock in the form of restricted stock units granted at a price of $0 per share.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. Following this grant, Lee beneficially owns 660,830.841 shares of Pacira common stock directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker reported routine equity transactions in company stock. On January 30, 2026, 2,751 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at $20.54 per share. On February 2, 2026, Riker sold 4,000 shares of common stock at a weighted average price of $20.81 per share, executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Riker directly beneficially owned about 52,313.242 shares of Pacira common stock.
Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions. On January 30, 2026, 17,134 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at a price of $20.54 per share, leaving her with 144,440 shares held directly.
On February 2, 2026, she sold 13,137 Pacira common shares at $20.53 per share in a transaction carried out under a pre-established Rule 10b5-1 trading plan. After this sale, she directly held 131,303 Pacira shares.
Pacira BioSciences Chief Medical Officer reports tax-share withholding. Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported a Form 4 transaction involving company common stock. On 01/30/2026, 6,168 shares of common stock were withheld by Pacira to cover tax obligations when a restricted stock unit award vested at a price of $20.54 per share.
After this withholding, Slonin directly beneficially owned 172,355.175 shares of Pacira common stock. The transaction reflects tax-related share withholding rather than an open-market sale.
Pacira BioSciences, Inc. reported a routine insider tax-withholding transaction by its Chief Commercial Officer, Brendan Teehan. On 01/30/2026, 5,182 shares of common stock were withheld by the company at $20.54 per share to cover tax obligations upon vesting of a restricted stock unit award. After this withholding, Teehan directly beneficially owned 49,220.268 shares of Pacira common stock.
Pacira BioSciences, Inc. CEO Lee Frank D. reported an automatic share withholding related to equity compensation. On January 30, 2026, 41,488 shares of common stock were withheld by Pacira at $20.54 per share to cover tax obligations on a vested restricted stock unit award.
After this tax withholding, Lee Frank D. directly beneficially owned 399,012.841 shares of Pacira common stock. The transaction reflects routine administration of equity compensation rather than an open-market trade.
Pacira BioSciences, Inc. director Samit Hirawat received a grant of stock options on January 27, 2026. The award covers 39,291 stock options with an exercise price of $19.85 per share, held directly, and represents a right to buy common stock.
According to the vesting terms, one-third of the options vest on the first anniversary of the grant date. The remaining options vest in equal monthly installments over the following two years, as long as the director continues in service. The options expire on January 27, 2036.
Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.
Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.
After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.
Pacira BioSciences, Inc. (PCRX) reported an insider stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 3,960 shares of Pacira common stock at a price of $24.09 per share, according to a Form 4 filing. After this transaction, the officer directly beneficially owned 178,367.009 shares of Pacira common stock.
The filing states that this sale was carried out under a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling stock that is intended to comply with securities regulations and provide an affirmative defense against insider trading claims.
Pacira BioSciences (PCRX) disclosed that its Chief Financial Officer sold 12,060 shares of common stock at $22.09 per share on 11/10/2025.
The transaction was executed under a Rule 10b5-1 trading plan. After this sale, the CFO beneficially owns 56,250 shares, held directly.
Pacira BioSciences (PCRX) reported an insider tax-withholding transaction by its CFO. On 10/31/2025, 6,690 shares of common stock were withheld by the company at $21.38 to cover taxes due upon restricted stock unit vesting.
Following the withholding, the officer directly beneficially owns 68,310 shares. The filing lists the transaction code as F, which denotes shares withheld for tax obligations related to equity awards.